Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levo-bencyclane hydrochloride
- Development stage
- Unknown
- Lead developer
- Beijing Institute of Pharmacology and Toxicology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Levo-bencyclane hydrochloride is the levorotatory enantiomer of bencyclane, a synthetic vasodilator and antispasmodic agent. Developed by the Institute of Toxicology and Pharmacology at the Academy of Military Medical Sciences in China, it is primarily investigated for the prevention of motion sickness (specifically carsickness). The drug acts as a calcium channel blocker and also exhibits local anesthetic and anti-serotonin properties. By inhibiting calcium influx into smooth muscle cells and potentially modulating vestibular sensitivity, it helps alleviate symptoms of motion-induced nausea and dizziness. It has been evaluated in Phase 3 clinical trials in China, where its efficacy and safety were compared against placebo and the racemic form of bencyclane hydrochloride.
- Other names
- l-bencyclane hydrochloridelevobencyclane hydrochloride
02
Targets
ADRB1 (β1)PDE (Phosphodiesterase family)CaV (Voltage-gated calcium channel protein complex)ADRA1A (α1A)
Beyond the preview
Go deeper on levo-bencyclane hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levo-bencyclane hydrochloride.